1. A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021) Authors: Feagan, B G; Loftus, E V; Danese, S; Vermeire, S; Sandborn, W J; Ritter, T; Mehta, R; Seidler, U; Seibold, F; Beales, I; Kim, H; McNally, J; Yun, C; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 4(2021)Supplement 1 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021) Authors: Peyrin-Biroulet, L; Loftus, E V; Danese, S; Vermeire, S; Sandborn, W J; Fogel, R; Nijhawan, S; Kempinski, R; Filip, R; Hospodarskyy, I; McNally, J; Yun, C; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G; Hibi, T Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 4(2021)Supplement 1 Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Issue 6 (19th December 2016) Authors: Westhovens, R; Taylor, P C; Alten, R; Pavlova, D; Enríquez-Sosa, F; Mazur, M; Greenwald, M; Van der Aa, A; Vanhoutte, F; Tasset, C; Harrison, P Journal: Annals of the rheumatic diseases Issue: Volume 76:Issue 6(2017) Page Start: 998 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Issue 6 (19th December 2016) Authors: Kavanaugh, A; Kremer, J; Ponce, L; Cseuz, R; Reshetko, O V; Stanislavchuk, M; Greenwald, M; Van der Aa, A; Vanhoutte, F; Tasset, C; Harrison, P Journal: Annals of the rheumatic diseases Issue: Volume 76:Issue 6(2017) Page Start: 1009 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn's disease: results from the phase ii fitzroy study. (17th June 2017) Authors: Keshav, S; Goh, J; Hart, A; Levison, S; McLaughlin, S; der, Avan Aa; Galien, R; Pan, Y; Meuleners, L; Jamoul, C; Tasset, C; Harrison, P; Vermeire, S Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0229 Effect of baseline serum crp levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies. (15th June 2017) Authors: Westhovens, R; Kavanaugh, A; Jamoul, C; Tasset, C; Harrison, P; Aa, A Van der Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P633 Concordance between endoscopy and histology scores at baseline and following induction therapy with the JAK1 inhibitor filgotinib in active Crohn's disease: Results from FITZROY study. (16th January 2018) Authors: Reinisch, W; De Hertogh, G; D'Haens, G; Li, W; Serone, A; Tasset, C; Van der Aa, A; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PTU-003 Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active crohn's disease. (8th June 2018) Authors: Keshav, Satish; Roblin, X; D'Haens, G; Galien, R; Goyal, L; Li, W; Mirza, A; Serone, A; Tasset, C; Van der Aa, A; Woo, J; Vermeire, S Journal: Gut Issue: Volume 67(2018)Supplement 1 Page Start: A63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks. (15th June 2017) Authors: Alten, R; Westhovens, R; Kavanaugh, A; Genovese, M; Winthrop, K; Greenwald, M; Ponce, L; Enriquez, F; Stanislavchuk, M; Mazur, M; Spindler, A; Cseuz, R; Nikulenkova, N; Glowacka-Kulesz, M; Szombati, I; Dudek, A; Meuleners, L; Tasset, C; Harrison, P; Aa, A Van der Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. THU0182 Monotherapy with the jak1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients. (15th June 2017) Authors: Kavanaugh, A; Aa, A Van der; Jamoul, C; Li, W; Goyal, L; Pan, Y; Harrison, P; Tasset, C; Tarrant, J; Galien, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 270 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗